Market Overview:
The global hemotransmissive infections testing market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hematological malignancies, rising awareness about hematological disorders, and technological advancements in the field of hematology. The global hemotransmissive infections testing market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into hepatitis B virus (HBV) DNA testing, hepatitis C virus (HCV) RNA testing, human immunodeficiency virus (HIV) types 1 and 2 RNA Testing Hemotransmissive Infections Testin). On the basis of application,the market is segmented into hospital clinics Others).Onthebasisofregion,. S.),bioMérieuxSA(France),F Hoffmann-La Roche Ltd.(Switzerland),QIAGENNetherlandsBV(Netherlands),SysmexCorp.(Japan),Thermo FisherScientificInc.(U.S.(U.S.).
Product Definition:
A hemotransmissive infection is a type of infection that can be spread through contact with blood or other bodily fluids. Hemotransmissive infections can be serious and require treatment to prevent the spread of the infection. Hemotransmissive infections tests are used to screen for and diagnose these types of infections.
Hepatitis B virus (HBV) DNA Testing:
The Hepatitis B virus (HBV) DNA testing market is expected to grow at a lucrative rate during the forecast period. The HBV infection can lead to several chronic diseases including liver cancer, liver failure and other disorders. According to the Centers for Disease Control and Prevention (CDC), an estimated 1.4 million people in U.
Hepatitis C virus (HCV) RNA Testing:
Hepatitis C virus (HCV) RNA testing is used for the detection of Hepatitis C Virus (HCV). HCV infection can lead to several complications such as liver cancer, liver failure, and chronic inflammation of the liver. The most common symptoms associated with HCV infection include jaundice, fatigue, nausea, right upper quadrant pain; however; some patients may not experience any symptoms at all.
Global Hepatitis C Virus RNA Testing.
Application Insights:
Based on application, the market is segmented into hospital, clinic and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as increasing prevalence of chronic conditions that require frequent monitoring and treatment along with an increase in government funding for the development of diagnostic tests for HBV & HCV infections.
The other applications include laboratories, hospitals and clinics outside India where genotype-specific anti-viral therapy (HAVT) is used according to a patient¢â‚¬â„¢s HIV RNA level or HBV DNA level or both are positive when diagnosed by an Indian laboratory standard test. Thus, this testing method has become popular among patients seeking care outside India owing to its low cost compared to those conducted inside a clinical setting which aids affordability without compromising on quality thus driving growth over the forecast period.
Regional Analysis:
North America dominated the global hematransmissive infections testing market in 2017. This can be attributed to the presence of a large number of laboratories, increase in awareness levels pertaining to HIV/AIDS and hepatitis B virus (HBV) infection, and availability of effective treatment for these diseases. In addition, increasing incidence rate of these infections is also expected to boost demand for such tests during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising prevalence rates for various infectious diseases coupled with growing healthcare expenditure by governments as well as individuals. Moreover, increasing penetration rate of insurance services will further fuel revenue generation opportunities in this region during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of hemotransmissive infections
- Growing demand for rapid and accurate diagnosis of hemotransmissive infections
- Rising awareness about benefits of early diagnosis and treatment of hemotransmissive infections
- Technological advancements in Hemotransmissive Infections Testing market
- Growing number of private diagnostic laboratories
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemotransmissive Infections Testing Market Research Report
By Type
Hepatitis B virus (HBV) DNA Testing, Hepatitis C virus (HCV) RNA Testing, Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing, Hemotransmissive Infections Testin
By Application
Hospital, Clinic, Others
By Companies
Vector-Best, Atlas Medical, Launch Diagnostics, Creative Diagnostics, Shanghai Chemtron Biotech, Oscar Medicare, ABON Biopharm, Bio-Rad Laboratories, Trinity Biotech Manufacturing, Adaltis, Hemotransmissive Infections Testin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Hemotransmissive Infections Testing Market Report Segments:
The global Hemotransmissive Infections Testing market is segmented on the basis of:
Types
Hepatitis B virus (HBV) DNA Testing, Hepatitis C virus (HCV) RNA Testing, Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing, Hemotransmissive Infections Testin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Vector-Best
- Atlas Medical
- Launch Diagnostics
- Creative Diagnostics
- Shanghai Chemtron Biotech
- Oscar Medicare
- ABON Biopharm
- Bio-Rad Laboratories
- Trinity Biotech Manufacturing
- Adaltis
- Hemotransmissive Infections Testin
Highlights of The Hemotransmissive Infections Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hepatitis B virus (HBV) DNA Testing
- Hepatitis C virus (HCV) RNA Testing
- Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
- Hemotransmissive Infections Testin
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemotransmissive Infections Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemotransmissive infections testing is a type of blood test that checks for signs of infection in the blood. This test can be used to check for infections such as pneumonia, bronchitis, and other respiratory illnesses.
Some of the major players in the hemotransmissive infections testing market are Vector-Best, Atlas Medical, Launch Diagnostics, Creative Diagnostics, Shanghai Chemtron Biotech, Oscar Medicare, ABON Biopharm, Bio-Rad Laboratories, Trinity Biotech Manufacturing, Adaltis, Hemotransmissive Infections Testin.
The hemotransmissive infections testing market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemotransmissive Infections Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemotransmissive Infections Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemotransmissive Infections Testing Market - Supply Chain
4.5. Global Hemotransmissive Infections Testing Market Forecast
4.5.1. Hemotransmissive Infections Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemotransmissive Infections Testing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemotransmissive Infections Testing Market Absolute $ Opportunity
5. Global Hemotransmissive Infections Testing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
5.3.1. Hepatitis B virus (HBV) DNA Testing
5.3.2. Hepatitis C virus (HCV) RNA Testing
5.3.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
5.3.4. Hemotransmissive Infections Testin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemotransmissive Infections Testing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemotransmissive Infections Testing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemotransmissive Infections Testing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemotransmissive Infections Testing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemotransmissive Infections Testing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemotransmissive Infections Testing Demand Share Forecast, 2019-2026
9. North America Hemotransmissive Infections Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemotransmissive Infections Testing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
9.7.1. Hepatitis B virus (HBV) DNA Testing
9.7.2. Hepatitis C virus (HCV) RNA Testing
9.7.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
9.7.4. Hemotransmissive Infections Testin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemotransmissive Infections Testing Demand Share Forecast, 2019-2026
10. Latin America Hemotransmissive Infections Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemotransmissive Infections Testing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
10.7.1. Hepatitis B virus (HBV) DNA Testing
10.7.2. Hepatitis C virus (HCV) RNA Testing
10.7.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
10.7.4. Hemotransmissive Infections Testin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemotransmissive Infections Testing Demand Share Forecast, 2019-2026
11. Europe Hemotransmissive Infections Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemotransmissive Infections Testing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
11.7.1. Hepatitis B virus (HBV) DNA Testing
11.7.2. Hepatitis C virus (HCV) RNA Testing
11.7.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
11.7.4. Hemotransmissive Infections Testin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemotransmissive Infections Testing Demand Share, 2019-2026
12. Asia Pacific Hemotransmissive Infections Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemotransmissive Infections Testing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
12.7.1. Hepatitis B virus (HBV) DNA Testing
12.7.2. Hepatitis C virus (HCV) RNA Testing
12.7.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
12.7.4. Hemotransmissive Infections Testin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemotransmissive Infections Testing Demand Share, 2019-2026
13. Middle East & Africa Hemotransmissive Infections Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemotransmissive Infections Testing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemotransmissive Infections Testing Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemotransmissive Infections Testing Market Size and Volume Forecast by Type
13.7.1. Hepatitis B virus (HBV) DNA Testing
13.7.2. Hepatitis C virus (HCV) RNA Testing
13.7.3. Human immunodeficiency virus (HIV) types 1 and 2 RNA Testing
13.7.4. Hemotransmissive Infections Testin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemotransmissive Infections Testing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemotransmissive Infections Testing Market: Market Share Analysis
14.2. Hemotransmissive Infections Testing Distributors and Customers
14.3. Hemotransmissive Infections Testing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Vector-Best
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Atlas Medical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Launch Diagnostics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Creative Diagnostics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shanghai Chemtron Biotech
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Oscar Medicare
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. ABON Biopharm
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bio-Rad Laboratories
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Trinity Biotech Manufacturing
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Adaltis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hemotransmissive Infections Testin
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
